Literature DB >> 28302482

FAP positive fibroblasts induce immune checkpoint blockade resistance in colorectal cancer via promoting immunosuppression.

Lingling Chen1, Xiangting Qiu1, Xinhua Wang1, Jian He2.   

Abstract

Immune checkpoint blockades that significantly prolonged survival of melanoma patients have been less effective on colorectal cancer (CRC) patients. Growing evidence suggested that fibroblast activation protein-alpha (FAP) on cancer associate fibroblasts (CAFs) has critical roles in regulating antitumor immune response by inducing tumor-promoting inflammation. In this study, we explored the roles of FAP in regulating the tumor immunity and immune checkpoint blockades resistance in CRC experimental systems. We found that CAFs with high FAP expression could induce immune checkpoint blockade resistance in CRC mouse model. Mechanistically, CAFs with high FAP expression promoted immunosuppression in the CRC tumor immune microenvironment by up-regulating CCL2 secretion, recruiting myeloid cells, and decreasing T-cell activity. In human CRC samples, FAP expression was proportional to myeloid cells number, but inversely related to T-cell number. High FAP expression also predicted poor survival of CRC patients. Taken together, our study suggested that high FAP expression in CAFs is one reason leading to immune checkpoint blockades resistance in CRC patients and FAP is an optional target for reversing immune checkpoint blockades resistance.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CCL2; Cancer-associated fibroblast; Colorectal cancer; Fibroblast activation protein-alpha; Immune checkpoint blockade

Mesh:

Substances:

Year:  2017        PMID: 28302482     DOI: 10.1016/j.bbrc.2017.03.039

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  33 in total

Review 1.  The role of fibroblast activation protein in health and malignancy.

Authors:  Allison A Fitzgerald; Louis M Weiner
Journal:  Cancer Metastasis Rev       Date:  2020-09       Impact factor: 9.264

Review 2.  Trial watch: DNA-based vaccines for oncological indications.

Authors:  Stefano Pierini; Renzo Perales-Linares; Mireia Uribe-Herranz; Jonathan G Pol; Laurence Zitvogel; Guido Kroemer; Andrea Facciabene; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2017-11-20       Impact factor: 8.110

Review 3.  Informing the new developments and future of cancer immunotherapy : Future of cancer immunotherapy.

Authors:  Atul Kumar; Courtney A Swain; Lalita A Shevde
Journal:  Cancer Metastasis Rev       Date:  2021-05-18       Impact factor: 9.264

4.  Negative correlations of psychological distress with quality of life and immunotherapy efficacy in patients with advanced NSCLC.

Authors:  Ziran Bi; Wen Li; Jie Zhao; Lulian Pang; Yanyan Jing; Xiuqing Zhang; Senbang Yao; Xiangxiang Yin; He Zuo; Huaidong Cheng
Journal:  Am J Cancer Res       Date:  2022-02-15       Impact factor: 6.166

5.  Fibroblast activation protein in the tumor microenvironment predicts outcomes of PD-1 blockade therapy in advanced non-small cell lung cancer.

Authors:  Yan Zhao; Yueping Liu; Yunlong Jia; Xiaoxiao Wang; Jiankun He; Shuman Zhen; Jiali Wang; Lihua Liu
Journal:  J Cancer Res Clin Oncol       Date:  2022-08-11       Impact factor: 4.322

6.  Immune microenvironment composition in high-grade serous ovarian cancers based on BRCA mutational status.

Authors:  Sara Corvigno; Jared K Burks; Wei Hu; Yanping Zhong; Nicholas B Jennings; Nicole D Fleming; Shannon N Westin; Bryan Fellman; Jinsong Liu; Anil K Sood
Journal:  J Cancer Res Clin Oncol       Date:  2021-09-02       Impact factor: 4.322

7.  Extracellular matrix directs phenotypic heterogeneity of activated fibroblasts.

Authors:  Diana Avery; Priya Govindaraju; Michele Jacob; Leslie Todd; James Monslow; Ellen Puré
Journal:  Matrix Biol       Date:  2017-12-14       Impact factor: 11.583

Review 8.  Fibroblasts as immune regulators in infection, inflammation and cancer.

Authors:  Sarah Davidson; Mark Coles; Tom Thomas; George Kollias; Burkhard Ludewig; Shannon Turley; Michael Brenner; Christopher D Buckley
Journal:  Nat Rev Immunol       Date:  2021-04-28       Impact factor: 53.106

9.  JAK/STAT-Dependent Chimeric Antigen Receptor (CAR) Expression: A Design Benefiting From a Dual AND/OR Gate Aiming to Increase Specificity, Reduce Tumor Escape and Affect Tumor Microenvironment.

Authors:  Javad Khanali; Mohammadreza Azangou-Khyavy; Melika Boroomand-Saboor; Mobina Ghasemi; Hassan Niknejad
Journal:  Front Immunol       Date:  2021-06-09       Impact factor: 7.561

Review 10.  Cancer-Associated Fibroblast Heterogeneity: A Factor That Cannot Be Ignored in Immune Microenvironment Remodeling.

Authors:  Pei-Yu Chen; Wen-Fei Wei; Hong-Zhen Wu; Liang-Sheng Fan; Wei Wang
Journal:  Front Immunol       Date:  2021-07-08       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.